UK Markets closed

Celldex Therapeutics, Inc. (CLDX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
29.16+0.24 (+0.83%)
At close: 04:00PM EDT
30.61 +1.45 (+4.97%)
After hours: 07:35PM EDT

Celldex Therapeutics, Inc.

Perryville III Building
Suite 220 53 Frontage Road
Hampton, NJ 08827
United States
908 200 7500
https://www.celldex.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees132

Key executives

NameTitlePayExercisedYear born
Mr. Anthony S. Marucci M.B.A.Founder, Pres, CEO & Director1.18M20.16k1962
Dr. Tibor KelerFounder, Chief Scientific Officer & Exec. VP748.51kN/A1959
Mr. Sam MartinSr. VP, CFO, Sec. & Treasurer619.35k1.39M1971
Mr. Freddy A. Jimenez Esq.Sr. VP & Gen. Counsel579.7kN/A1969
Dr. Diane C. Young M.D.Sr. VP & Chief Medical Officer636k149.78k1957
Ms. Sarah CavanaughSr. VP of Corp. Affairs & Admin.N/AN/A1975
Patrick TillSr. Director of Investor Relations & Corp. CommunicationsN/AN/AN/A
Dr. Ronald A. PepinChief Bus. Officer & Sr. VPN/AN/A1956
Ms. Elizabeth CrowleyChief Product Devel. Officer & Sr. VPN/AN/A1972
Dr. Richard M. Wright Ph.D.Chief Commercial Officer & Sr. VPN/AN/A1964
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Corporate governance

Celldex Therapeutics, Inc.’s ISS governance QualityScore as of 1 May 2022 is 2. The pillar scores are Audit: 9; Board: 3; Shareholder rights: 1; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.